Drug intelligence / Profile preview

[18F]myo-2

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[18F]myo-2 is a novel [18F]fluoro-inositol-based radiotracer developed for Positron Emission Tomography (PET) imaging. It is equipped with a propyl linker bearing fluorine-18, either on a hydroxyl group (O-alkylated inositol) or on the cyclohexyl backbone (C-branched derivative). This radiotracer was synthesized in acetylated or hydroxylated form to modulate lipophilicity. In preliminary in vivo preclinical evaluation, [18F]myo-2 demonstrated the highest tumor uptake among tested inositols in a breast tumor-bearing mouse model, revealing its potential for monitoring breast cancer.

Beyond the preview

Go deeper on [18F]myo-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]myo-2.

Explore the full profile